CSV May 16, 2022 through May 16, 2024 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYC	*Assay*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
IN ETHYLSUCCINATE FOR ORAL SUSPENSION								Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the *Assay* under *Erythromycin Ethylsuccinate Oral Suspension*. to: Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed for erythromycin under *Antibiotics—Microbial Assays* ?81?, using an accurately measured

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								volume of the reconstituted suspension, freshly mixed and free from air bubbles, blended for 4 ± 1 minutes in a high-speed glass blender jar with sufficient methanol to give a stock solution containing the equivalent of about 1 mg of erythromycin per mL. Dilute this stock solution quantitatively with *Buffer B.3* to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Standard. In *Test 2*/*Analysis*: Change C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (ug/mL) in the *Standard solution* to: C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (µg/mL) in the *Standard solution*
ERYTHROMYCIN DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 1*: Change **Buffer stage Medium**: 0.05 M pH 6.8

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*) to: **Buffer stage** **Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*); 900 mL
CALCIUM LACTATE	CHEMICAL INFORMATION	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Calcium lactate (1:2) hydrate to: Calcium lactate hydrate AND Change Calcium lactate (1:2) pentahydrate to: Calcium lactate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								pentahydrate
THYROID	ASSAY/ *Procedure*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Chromatographic system*: Change **Column**: 4.6-cm × 25-cm; packing L1 to: **Column**: 4.6-mm × 25-cm; packing L1
PRAZOSIN HYDROCHLORIDE CAPSULES	ASSAY/ *Procedure*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Analysis*: Change C_S = concentration of USP Prazosin Hydrochloride RS in the *Standard solution* (µg/mL) C_U = nominal concentration of prazosin in the *Sample solution* (µg/mL) M_{r1} = molecular weight of prazosin,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								383.41 M_{r2} = molecular weight of prazosin hydrochloride, 419.86 to: C_S = concentration of USP Prazosin Hydrochloride RS in the *Standard solution* (mg/mL) C_U = nominal concentration of prazosin in the *Sample solution* (mg/mL) M_{r1} = molecular weight of prazosin, 383.41 M_{r2} = molecular weight of prazosin hydrochloride, 419.87
METAPROTER ENOL	*Identification/A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
SULFATE TABLETS								directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid (50:25:7) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:
MIRTAZAPINE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Resolution*: Change 10-ketomirtazpine to: 10-ketomirtazapine AND In *Table 1*: Change 1-Ketomirtazpine[c]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 1-Ketomirtazapine[c]
METAPROTERENOL SULFATE ORAL SOLUTION	*Identification*/*A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid (50:25:7) until the solvent front has moved

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:
SOTALOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of any unspecified impurities in the portion of Sotalol Hydrochloride taken: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ *r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$= sum of all the peak responses of all unspecified impurities from the *Sample solution* to: Calculate the percentage of any unspecified impurity in the portion of Sotalol Hydrochloride taken: Result = (r_U/r_S) × (C_S/C_U) × 100 r_U = peak response of each unspecified impurity from the *Sample solution* AND In *Table 1*: Change Any unspecified impurities to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION	*Assay for lidocaine hydrochloride*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Any unspecified impurity Change Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine and Epinephrine Injection*. to: Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine Hydrochloride and Epinephrine Injection.*
AZTEC MARIGOLD ZEAXANTHIN EXTRACT	COMPOSITION /*Procedure 4: Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *System suitability*/*Suitability requirements*/

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
ISOBUTYL ALCOHOL	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	*Resolution*: Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S* *meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin In *Analysis*: Change r_S = sum of all the peaks except those

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								each of which with an area less than 0.1 times the area of the major peak from the *Reference solution* to: r_T = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution*
FLUTICASONE PROPIONATE NASAL SPRAY	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Samples: *System suitability solution*, *Identification solution*, and *Sample solution* to: Samples:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-ZEAXANTHIN PREPARATION	COMPOSITION /*Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	*Identification solution* and *Sample solution* In *System suitability*: Change [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*-*meso*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] to: [Note—The approximate relative retention times for (3*S*,3?*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								)-zeaxanthin, (3*R*,3?*S*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] AND In *System suitability*/*Suitability requirements*/*Resolution*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S*-*meso*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
METARAMINOL BITARTRATE	SPECIFIC TESTS/*Content of Tartaric Acid*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Result = $\{[(V_S?V_B) \times N \times F]/2 \times W\} \times 100$ to: Result = $\{[(V_S?V_B) \times N \times F]/(2 \times W)\} \times 100$
CHLOROPROCAINE HYDROCHLORIDE INJECTION	ASSAY/*Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Sample solution*: Change Transfer about 100 mg of chloroprocaine hydrochloride to a 100-mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								volumetric flask, dissolve in 40 mL of methanol, and dilute with water to volume. to: Transfer a volume of Injection, equivalent to about 100 mg of chloroprocaine hydrochloride to a 100-mL volumetric flask, add 40 mL of methanol, and dilute with water to volume.
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF 1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL)	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
DEXAMETHASONE SODIUM PHOSPHATE INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r22}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
MESO-ZEAXANTHIN PREPARATION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP *meso* -Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to: (3*R*,3?*S*)-Zeaxanthin.
AZTEC MARIGOLD ZEAXANTHIN EXTRACT	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
METARAMINOL BITARTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards ?11?*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP Metaraminol Enantiomer RS: Change 3-[(1*S*,2*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								)-2-Amino-1-hydroxypropyl]phenol. $C_9H_{13}NO_2$ 167.21 to: 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol D-tartrate. $C_9H_{13}NO_2$? $C_4H_6O_6$ 317.29
MESO-ZEAXANTHIN PREPARATION	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
POTASSIUM GLUCONATE ORAL SOLUTION	SPECIFIC TESTS	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change **Alcohol Determination** ?611?, *Method II—Distillation Method*: to: **Alcohol Determination** ?611?, *Method I—Distillation*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
Methyl Acetate	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	*Method*: Change CAS RN®: 74-20-9. to: CAS RN®: 79-20-9.
PALONOSETRON HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *Limit of Unspecified Impurities*: Change **Mobile phase** and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Mobile phase**, **Standard stock solution**, and **Chromatographic system**: Proceed as directed in the *Assay*.
METOLAZONE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *Buffer*: Change 1.38 g of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								monobasic potassium phosphate monohydrate in 900 mL of water. to: 1.38 g of monobasic sodium phosphate in 900 mL of water.
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *System suitability*: Change **Samples**: *System suitability solution*, *Standard solution A*, and *Standard solution B* to: **Samples**: *System suitability solution* and *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								solution A AND In *Analysis*: Change **Samples**: *Mobile phase*, *Standard solution A*, and *Sample solution* Chromatograph the *Standard solution* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: **Samples**: *Mobile phase*, *Standard solution A*, *Standard solution B*, and *Sample solution* Chromatograph *Standard solution B* and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
0.1 M ZINC SULFATE VS	STANDARDIZATION	*USPNF Online*	Online	26-Aug-2022	1-Dec-2022	*NA*	*NA*	adjust the integration parameters so that the response is 5%–15% of full-scale deflection. In *Standardization with visual end point*: Change M = mL edetate disodium × edetate disodium/mL $ZnSO_4$ to: M = mL edetate disodium × M edetate disodium/mL $ZnSO_4$ AND In *Standardization with potentiometric end point*: Change M = mL edetate disodium ×

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								edetate disodium/mL $ZnSO_4$ to: M = mL edetate disodium × M edetate disodium/mL $ZnSO_4$
ZINC UNDECYLENATE	ASSAY/ *Procedure*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Solution A*: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Transfer 150 mL of 0.5 N hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well.
PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE INJECTABLE SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Test A*: Change It responds to the *Identification* test under *Penicillin G Benzathine Oral Suspension*: the spot obtained from the test solution, corresponding in R_F value to that obtained from the Standard solution, is completely resolved from a second spot, produced by

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								penicillin G procaine. to: Mix a portion of it with methanol to obtain a solution containing about 3000 Penicillin G Units per mL. Apply 20 µL of this test solution and 20 µL of a Standard solution of USP Penicillin G Benzathine RS in methanol containing 2.5 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel, and allow

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								the spots to dry. Using an unlined developing chamber, develop the chromatogram in a solvent system consisting of a mixture of methanol, acetonitrile, and ammonium hydroxide (70:30:3) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, and allow to air-dry. Spray the plate uniformly with a spray reagent prepared as follows.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Dissolve 20 g of tartaric acid and 1.7 g of bismuth subnitrate in 80 mL of water. Add 2.5 mL of this solution, 2.5 mL of potassium iodide solution (4 in 10), and 10 g of tartaric acid to 50 mL of water, and mix. Examine the chromatograms: the principal spot obtained from the test solution corresponds in R_F value to that obtained from the Standard solution. The spot obtained from the test solution, corresponding in R_F value to that obtained

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								from the Standard solution, is completely resolved from a second spot, produced by penicillin G procaine.
CHROMATOGRAPHY	ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS	*USPNF Online*	Online	26-Aug-2022	1-Dec-2022	*NA*	*NA*	In *Liquid Chromatography: Isocratic Elution/Injection volume*: Change L_2 = internal diameter of the column used (mm) dc_1 = particle size indicated in the monograph (µm) dc_2 = particle size of the column used (µm) to: L_2 = new column length (mm)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								dc_1 = column internal diameter indicated in the monograph (mm) dc_2 = new column internal diameter (mm)
ENZACAMENE	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of enzacamene in the *Sample solution* (mg/mL) to: C_U = concentration of Enzacamene in the *Sample solution* (mg/mL)
NALOXONE HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Limit of Naloxone Related Compound D*: Delete **Sensitivity solution**: 1.25

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								µg/mL of USP Naloxone Related Compound D RS in 0.1 N hydrochloric acid AND In *System suitability*/*Samples*: Delete *Sensitivity solution*, AND In *System suitability*/*Suitability requirements*: Delete **Signal-to-noise ratio**: NLT 10, *Sensitivity solution*
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* <*711*>	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Test 6*: Change **Times**: 0.5, 1, and 4 h—for strengths 540 and 1080 mg as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								potassium citrate monohydrate; 0.5, 1, and 6 h—for strength 1620 mg as potassium citrate monohydrate. to: **Times**: 0.5, 1, and 4 h—for strength 540 mg as potassium citrate monohydrate; 0.5, 1, and 6 h—for strengths 1080 and 1620 mg as potassium citrate monohydrate.
N-Benzoyl-L-arginine Ethyl Ester Hydrochloride	REAGENT SPECIFICATIONS	*USPNF Online*	Online	30-Sep-2022	1-Dec-2022	*NA*	*NA*	Change Crystallized Trypsin (USP Monograph). to: Trypsin (USP Monograph).
ROCURONIUM IM		*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*USPNF 2023*	In footnote b of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
BROMIDE	PUR ITIES/*Organic Impurities*						*Issue 3*	*Table 1*: Change 2?-(Morpholin-4-yl)-16?-(pyrrolidin-1-yl)-5?-androstan-3?,17?-diol. to: 2?-(Morpholin-4-yl)-16?-(pyrrolidin-1-yl)-5?-androstane-3?,17?-diol.
LATANOPROST	ASSAY/ *Procedure*	*USPNF Online*	Online	29-Jul-2022	1-Dec-2022	*NA*	*NA*	Change **Standard solution**: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution: Transfer 2.0 mg/mL of Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. to: **Standard solution**: 2.0 mg/mL of USP Latanoprost RS prepared as follows. Transfer USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. **Sample solution**: 2.0 mg/mL of Latanoprost prepared as follows. Transfer Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume.
CHLORHEXIDINE GLUCONATE	IMPURITIES/*Limit of p-*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Standard solution**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL RINSE	*Chloroaniline*							: 1.0 µg/mL of USP *p*-Chloroaniline RS in *Diluent* to: **Standard solution**: 0.001 mg/mL of USP *p*-Chloroaniline RS in *Diluent* AND In *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times D \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND Delete *D* = dilution factor for the *Sample solution*, 2.5
MOMETASONE FUROATE TOPICAL SOLUTION	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In test *A*: Change The retention time of the major peak of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								solution corresponds to that of the *Standard solution*, both relative to the internal standard, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
MAGNESIUM OXIDE	IM PURITIES/*Limit of Calcium*	*USPNF Online*	Online	25-Feb-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of Magnesium Hydroxide in the *Sample solution* (mg/mL) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = concentration of Magnesium Oxide in the *Sample solution* (mg/mL)
FELODIPINE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solution**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solution**, **Sample solution**, and **Chromatographic system**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
PENICILLIN G BENZATHINE INJECTABLE SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	: Proceed as directed in the *Assay*, and use 40 µL injection volume for the *Sensitivity solution*. Change It responds to the *Identification test* under *Penicillin G Benzathine Oral Suspension*. to: Mix a portion of it with methanol to obtain a solution containing about 3000 Penicillin G Units per mL. Apply 20 µL of this test solution and 20 µL of a Standard solution of USP Penicillin G

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Benzathine RS in methanol containing 2.5 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel, and allow the spots to dry. Using an unlined developing chamber, develop the chromatogram in a solvent system consisting of a mixture of methanol, acetonitrile, and ammonium hydroxide (70:30:3) until the solvent front

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, and allow to air-dry. Spray the plate uniformly with a spray reagent prepared as follows. Dissolve 20 g of tartaric acid and 1.7 g of bismuth subnitrate in 80 mL of water. Add 2.5 mL of this solution, 2.5 mL of potassium iodide solution (4 in 10), and 10 g of tartaric acid to 50 mL of water, and mix. Examine the chromatograms: the principal

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								spot obtained from the test solution corresponds in R_F value to that obtained from the Standard solution.
CHROMATOGRAPHY	ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS	*USPNF Online*	Online	29-Apr-2022	1-Dec-2022	*NA*	*NA*	In *Liquid Chromatography: Isocratic Elution/Injection volume*: Change Result = (V_{inj2} = V_{inj1} (L_2 d_{c2}^2)/(L_1 d_{c1}^2) to: V_{inj2} = V_{inj1} (L_2 d_{c2}^2)/(L_1 d_{c1}^2) AND In *Liquid Chromatography: Gradient Elution/Column parameters and flow rate*: Change F_2 = F_2 × [(dc_2^2 × dp_1)/(dc_1^2 × *dp*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{2})]$ to: $F_2 = F_1 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$
PRIMIDONE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Sample solution*: Change 0.05 mg/mL of primidone from the *Standard stock solution* in *Diluent* to: 0.05 mg/mL of primidone from the *Sample stock solution* in *Diluent*
ADIPIC ACID	IM PUR ITIES/*Related Substances*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	In *Table 2*: Change Pimelic acid 1.21 0.91 Valeric acid 1.21 0.91 to: Pimelic acid 1.21 0.91 Valeric acid 1.46 0.88
ROCURONIUM	CHEMICAL	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*USPNF 2023*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
BROMIDE	INFORMATION						*Issue 3*	609.68 to: 609.69
CHROMATOGRAPHY	SYSTEM SUITABILITY	*USPNF Online*	Online	25-Mar-2022	1-Dec-2022	*NA*	*NA*	Change **System Repeatability—Assay of an Active Substance or an Excipient** to: **System Repeatability**
DOXORUBICIN HYDROCHLORIDE INJECTION	IMPURITIES/*Organic Impurities*	*USPNF 2022 Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DOXAZOSIN MESYLATE	IMPURITIES/*Organic*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							C_S = concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL) to: C_S = concentration of the corresponding USP Reference Standard or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL)

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Current page 4
- Page 5
- Page 6
- Next page Next ›
- Last page Last »